Champlain Investment Partners LLC Sells 109,167 Shares of Edwards Lifesciences Corporation $EW

Champlain Investment Partners LLC lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,114,537 shares of the medical research company’s stock after selling 109,167 shares during the period. Edwards Lifesciences accounts for 1.2% of Champlain Investment Partners LLC’s holdings, making the stock its 21st biggest holding. Champlain Investment Partners LLC’s holdings in Edwards Lifesciences were worth $164,448,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Vanguard Group Inc. lifted its holdings in Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after buying an additional 365,581 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the period. Jennison Associates LLC raised its position in shares of Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after acquiring an additional 2,287,783 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 0.4% in the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after acquiring an additional 45,555 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after acquiring an additional 4,805,819 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $87.27 on Tuesday. The business has a 50-day simple moving average of $82.75 and a 200 day simple moving average of $81.34. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The firm has a market capitalization of $50.69 billion, a price-to-earnings ratio of 47.69, a PEG ratio of 2.26 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on EW. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Sanford C. Bernstein restated a “market perform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Monday, November 3rd. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a report on Monday, November 3rd. Finally, Evercore reissued an “outperform” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,827,387.38. This trade represents a 34.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 79,144 shares of company stock valued at $6,685,688. 0.34% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.